Related Experiment Videos
Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice
1Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA. pridker@partners.org.
Insights
High-sensitivity C-reactive protein (hsCRP) effectively predicts cardiovascular risk. Measuring hsCRP guides interventions like diet, exercise, and statin therapy for better patient outcomes.
Area of Science:
- Cardiology
- Inflammation Biology
Background:
- Inflammation is a key factor in atherothrombotic disease.
- High-sensitivity C-reactive protein (hsCRP) is a validated biomarker for cardiovascular risk assessment.
- Physicians increasingly use hsCRP alongside cholesterol for global risk prediction.
Purpose of the Study:
- To provide a clinical overview of hsCRP measurement.
- To guide interpretation of hsCRP results.
- To inform targeted interventions for vascular risk reduction based on hsCRP levels.
Main Methods:
- Review of clinical guidelines and evidence regarding hsCRP.
- Analysis of hsCRP levels in relation to cardiovascular event risk.
- Identification of interventions that impact hsCRP levels.
Main Results:
- hsCRP levels (<1, 1-3, >3 mg/L) correlate with lower, moderate, and higher cardiovascular risk.
- Risk stratification by hsCRP is consistent across different Framingham Risk Scores and metabolic syndrome statuses.
- Lifestyle changes and medical therapies (e.g., statins) can reduce hsCRP.
Conclusions:
- hsCRP is a valuable tool for predicting cardiovascular events in primary and secondary prevention.
- hsCRP measurement aids in tailoring therapeutic strategies.
- Interventions targeting hsCRP can mitigate vascular risk.
Abstract:
Inflammation is now recognized as a critical contributor to the atherothrombotic process, and measurement of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) is a proven method to better predict cardiovascular risk and target therapeutic interventions. Following recommendations from the Centers for Disease Control and the American Heart Association, many physicians now routinely evaluate hsCRP along with cholesterol levels as a part of global risk prediction. Levels of hsCRP <1, 1-3, and >3 mg/L correspond to lower, moderate, and higher risk of cardiovascular events at all levels of the Framingham Risk Score and at all levels of metabolic syndrome. Interventions that lower hsCRP include diet, exercise, smoking cessation, statin therapy, and improved glycemic control. In addition to primary prevention, hsCRP is an important prognostic marker in acute coronary syndromes, following angioplasty, and in the long-term management of post-infarction patients. This article provides a clinically oriented overview of appropriate settings in which to measure hsCRP, how to interpret results, and how interventions to reduce vascular risk can be targeted on the basis of hsCRP findings.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:26Atherosclerosis III: Management
01:23Rheumatic Heart Disease I: Introduction
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:30Acute Coronary Syndrome III: Diagnostic Studies